Ibritumomab Tiuxetan Product Approval Information - Licensing Action

Proper name: Ibritumomab Tiuxetan
Tradename: Zevalin
Manufacturer: IDEC Pharmaceuticals Corp, San Diego, CA, License #1235
Indication for Use: Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin’s lymphoma. The therapeutic regimen includes Rituximab, Indium-111 Ibritumomab Tiuxetan, and Yttrium-90 Ibritumomab Tiuxetan
Approval Date: 2/19/2002
Type of submission: Biologics license application


Approval Letter (PDF)

Label (PDF)


Page Last Updated: 04/06/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English